BAP1 and mesothelioma: Supporting the idea that BAP1 mutant cancers actually confers loss of PcG repression rather than the previously assumed hyperactivation of PRC1 and PRC2 activities, is the lack of response of BAP1 mutant mesothelioma patients to the EZH2 inhibitor Tazemetostat (Zauderer et al., 2022).